BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, January 14, 2025
Home
»
Newsletters
» BioWorld MedTech
BioWorld MedTech
March 15, 2019
View Archived Issues
Guardant sees $8B+ valuation only months post-IPO, as it and Natera pop on earnings optimism
Read More
Stakeholders argue for inclusion of non-SaMD in FDA's pre-cert 1.0
Read More
Senate budget hearing turns spotlight on everything HHS
Read More
Other news to note
Read More
Financings
Read More
Daily M&A
Read More
Product briefs
Read More
BioWorld MedTech's Diagnostics Extra
Read More
U.K.'s MHRA investigating safety of paclitaxel-eluting stents and balloons in PAD treatment
LONDON – The U.K. Medicines and Healthcare products Agency (MHRA) has followed the U.S. FDA's lead and ordered an investigation into the safety of paclitaxel eluting balloons and stents in the treatment of peripheral arterial disease.
Read More
Australia to accept conformity assessments from U.K. NBs in no-deal Brexit scenario
Read More
